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nLate gadolinium enhancement (LGE) using cardiac
magnetic resonance (CMR) has emerged as the
gold-standard technique for imaging of myocardial
scar. The basic principle is inversion-recovery im-
aging after a 5- to 10-min delay following intrave-
nous administration of gadolinium contrast (1).
With appropriate settings, normal myocardium ap-
pears nulled or black, whereas nonviable regions
appear bright or enhanced. The mechanism under-
See page 150
lying LGE is not fully understood but is likely based
on the inability of gadolinium chelates to cross
intact cell membranes (2). In normal myocardium,
myocytes are densely packed, and tissue volume is
predominately intracellular (75% to 80%). There-
fore, the distribution volume of gadolinium is small,
and tissue concentration is low in a typical “voxel” of
normal myocardium. With acute necrosis (acute
myocardial infarction [MI], myocarditis, etc.), there
is membrane rupture, which allows gadolinium to
diffuse into myocytes. This results in increased
gadolinium concentration (3), shortened T1 relax-
ation time, and consequent signal enhancement. In
the chronic setting, scar has replaced necrotic tissue,
and the interstitial space is expanded. This again
leads to increased gadolinium concentration (3) and
hyperenhancement. In both acute and chronic set-
tings, one can consider viable myocytes as actively
excluding gadolinium contrast. Thus, the unifying
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iable myocytes rather than any inherent properties
hat are specific for acute necrosis, collagenous scar,
r other forms of nonviable myocardium.
LGE by CMR was initially validated in animal
odels of MI, with extensive comparisons demon-
trating a nearly exact relationship between the size
nd shape of infarcted myocardium by LGE to that
f histopathology (4,5). These initial studies used a
ignal intensity threshold of 2 or 3 standard devia-
ions (SD) above normal myocardium to define the
nfarct. However, these experimental protocols used
igh-resolution (0.5  0.5  0.5 mm) ex vivo
maging. Unfortunately, typical in vivo LGE imag-
ng has voxels that are over 100 times larger. In
ddition, in vivo imaging is complicated by blurring
rom associated cardiac motion. This results in
ignificantly more partial volume effects compared
ith ex vivo imaging, creating voxels with interme-
iate (gray) signal intensity containing an admixture
f viable and nonviable myocytes—particularly at
he infarct boundary. In this situation, using a low
hreshold (like 2 SD) may lead to overestimation of
nfarct size if these gray or intermediate signal
ntensity voxels are categorized as completely in-
arcted.
Thus, in vivo quantification of LGE is compli-
ated by unavoidable partial volume effects. In
eality, not all myocytes are dead within all infarcted
r scarred regions. Thus, significant “patchy” or
gray” regions, presumably due to partial volume
ffects from a mixture of viable and nonviable
yocardium, are not infrequently seen both in the
etting of myocardial infarction and in other con-
itions such as hypertrophic cardiomyopathy. The
elative signal intensity of the voxels in these regions
ill depend on the exact mixture of viable and
onviable myocytes contained within them.
It is on this background that the question of theest method for measurement of scar size using
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158LGE arises. Higher signal intensity cutoffs have
been used in an attempt to avoid overestimation of
scar size measurements due to the mechanisms
described in the preceding text. However, these
may potentially underestimate scar size if there are
significant areas of intermediate signal intensity,
and are highly dependent on the choice of the
remote zone used to calculate the threshold. An
alternative method using a threshold of 50% of the
maximum intensity within the scar—full-width at
half maximum (FWHM)—has been proposed as
being more resistant to surface-coil intensity varia-
tions, with good correlation to infarct size in an
animal model (6). However, this method assumes a
bright infarct core and may not be accurate in
homogeneously gray scars. In addition, multiple
separate islands of scar may cause difficulties with
this analysis method (7).
In this issue of iJACC, Flett et al. (8) address the
issue of intra- and interobserver variability of the
various techniques for measurement of myocardial
scar in patients with acute and chronic MI, as well
as with hypertrophic cardiomyopathy. This is an
important question and potentially has significant
implications for sample size requirements in clinical
trials using scar size as a surrogate outcome. Given
the effectiveness of current therapies in acute MI,
demonstrating further additive mortality reduction
is becoming increasingly difficult, necessitating very
large sample sizes. The costs and logistics of con-
ducting such large studies limits the number of new
therapies that can be tested. For this reason, there is
growing interest in the use of LGE measured
infarct size as a surrogate end point in acute MI
trials.
Flett et al. (8) demonstrate that scar size varies
significantly depending on the method of measure-
ment, with the 2SD method giving significantly
larger sizes. There was no statistically significant
difference between scar volume by manual,
FWHM, 5SD, and 6SD methods. The intra- and
interobserver agreement of the different techniques
was assessed using the intraclass correlation coeffi-
cient (ICC). This showed that the FWHM tech-
nique had the lowest ICC, which the authors
therefore suggest as being the “most reproducible”
technique for measuring LGE size. Interestingly,
the ICC was lowest for all techniques in patients
with hypertrophic cardiomyopathy compared with
MI patients. Finally, the authors estimate sample
size requirements for randomized trials with paired
and unpaired comparisons using the different tech-
niques. Their calculations suggest significant reduc-tions in sample size requirements with the use of
the FWHM technique.
The authors are to be commended for exploring
this understudied but important issue. It should be
emphasized at the outset that none of these tech-
niques are truly automated or objective. They all
require considerable human input to distinguish
bright artifact and/or noise, as well as dark no-
reflow regions. More importantly, all require man-
ual tracing of the myocardial borders. This is
because there are currently no automated algo-
rithms that reliably distinguish cavity from the
endocardial border of infarct. Moreover, since
ischemic injury progresses as a “wave front” from
subendocardium to epicardium, this border is prob-
ably the largest source of variability in infarct size
assessment. Given these issues, some investigators
have preferred to use manual planimetry or visual
estimation on a per-segment basis and tried to
account for intermediate-intensity regions by sub-
jectively giving a lower weighting to these regions
based on the highest-intensity signal in either the
infarct or blood cavity (whichever is higher) (9,10).
They have reported low intra- and interobserver
variability, for example, SD of differences of 2.6%
for interobserver variability and SD of differences of
0.8% for intraobserver variability in the setting of
chronic MI. However, it is difficult to compare
these numbers with the present study since variabil-
ity is not reported in the same manner. In the
current study, it is unclear how Flett et al. (8) dealt
with intermediate-intensity regions in their manual
readings. One can speculate that a predefined
method for dealing with these regions may have
altered the reported variabilities.
These findings echo those of another recent
study comparing scar quantitation methods in hy-
pertrophic cardiomyopathy (11). Intraobserver vari-
ability was reported as showing lower SD of differ-
ences for the FWHM technique compared with
manual assessment but with similar ICC for both
methods. They also showed that when compared
with the manual technique, the 6SD and FWHM
methods had the lowest SD of differences. It would
have been interesting to see the results of such a
comparison in the current study of Flett et al. (8).
Whether these findings are applicable to scar
measurements with phase-sensitive inversion-
recovery image reconstruction methods would be of
interest as these are increasingly used in some
centers (12). In addition, development of higher-
resolution techniques at increased field strengths
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159will likely affect variability of LGE size measure-
ments and will require investigation as these tech-
nologies evolve (13).
Flett et al. (8) also emphasize the importance of
their findings to sample size reductions in clinical
trials. However, there is an important difference
between trials using paired studies, for example,
those with CMR performed before and after a
treatment, as compared with unpaired studies
where only 1 CMR is performed after randomiza-
tion to treatment. The variability in paired studies
needs to take into account the interscan variability
i.e., between 2 separate scans performed on the
ame individual at different times) as well as the
ntra/interobserver variability with these techniques.
nterscan variability was not assessed in the study of
lett et al. (8), which limits the extension of their
ndings to paired studies. Clearly, paired studies
ould be preferable in future trials looking at scar
ize in hypertrophic cardiomyopathy, since they
equire significantly lower sample sizes. This is
ecause interpatient variability is no longer a sig-
ificant cause of variation. In contrast, paired test-
ng is not feasible in most acute MI trials, and
nfarct size is only assessed after the treatment has
een given.
Conclusions
All methods for assessment of scar size requireRelationship of MRI delayed contrast Med 2009;6:e1000they may initially sound. Flett et al. (8) have
confirmed previous studies showing significant dif-
ferences in scar size when measured by different
techniques. They also suggest that the FWHM
technique has the lowest intra- and interobserver
variability. Although direct comparisons are diffi-
cult, others have reported very low intra- and
interobserver variability using a refined visual tech-
nique method that tries to subjectively account for
partial volume effects. Future studies should directly
compare these methods. In addition, interscan vari-
ability needs to be assessed and compared by these
differing methods since it has significant impact on
sample sizes for paired studies. Future develop-
ments include refinement and testing of a number
of sophisticated computerized algorithms that have
been proposed based on assigning a weighting to
each voxel, depending on image intensity or re-
gional feature analysis (14–16). However, at the
present time, these techniques are not widely avail-
able, and most studies will continue to rely on 1 or
more of the current methods.
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